Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. GH.NASDAQ

Guardant Health Inc (GH NASDAQ) stock market data APIs

$32.73 -0.27(-0.8%) as of July 26, 2024
Price chart is built with Anychart

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Guardant Health Inc Financial Data Overview

33
32.73
-
33.53
31.8
15.81-41.06
3 907 M
122 M
604 M
-0.94
1.13
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'GH',
Type: 'Common Stock',
Name: 'Guardant Health Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG006D97VY9',
ISIN: NULL,
CUSIP: NULL,
CIK: '1576280',
EmployerIdNumber: '45-4139254',
FiscalYearEnd: 'December',
IPODate: '2018-10-04',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Diagnostics & Research',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Guardant Health Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 604 M
  • EBITDA -401 604 992
  • Earnings Per Share -3.92
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Guardant Health Inc Earnings via APIs

  • Latest Release 2024-05-09
  • EPS/Forecast -0.85

Get Guardant Health Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Guardant Health Inc latest news via APIs

Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024

PALO ALTO, Calif., July 24, 2024--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 202...

Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance

Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors,...
Do you have any questions?
support@eodhistoricaldata.com